The firms will evaluate the expression of Scancell’s drug using GTC’s transgenic production platform.
GTC says its technology offers significant advantages for the development of proteins that are expected to be required in large commercial production quantities.
SC101 is designed to target Lewis y/b, a cell surface carbohydrate blood group antigen whose expression is very low in normal tissue but is over-expressed on breast, colorectal, endometrial, kidney, lung, pancreas and stomach tumors. Animal studies have demonstrated that tumor growth was inhibited by anti-Lewis y/b antibodies alone.